Aims The aim of this study was to identify a subset of patients at high risk of bleeding or
myocardial infarction from a percutaneous coronary intervention and to investigate whether …

It has been shown that bleeding complications are associated with higher mortality rates
among patients undergoing coronary angioplasty. Due to its properties, bivalirudin may …

Compared to unfractionated heparin (UFH), bivalirudin decreases bleeding during
percutaneous coronary interventions (PCIs). We sought to investigate the association …

Aims: Current recommendations on the use of bivalirudin in patients treated with
percutaneous coronary intervention (PCI) are mostly based on trials comparing bivalirudin …

Bivalirudin, a direct thrombin inhibitor, is as effective as unfractionated heparin (UFH), with
decreased bleeding in patients with acute coronary syndromes who undergo percutaneous …

Percutaneous coronary intervention with bivalirudin plus bail-out glycoprotein IIb/IIIa
inhibitors has been shown to be as effective as unfractionated heparin plus routine …

Background—Patients treated with bivalirudin in randomized clinical trials of percutaneous
coronary intervention generally have less bleeding but more acute stent thrombosis (ST) …

Low/medium-bleeding-risk populations undergoing percutaneous coronary intervention
(PCI) show significantly less bleeding with bivalirudin (BIV) than with unfractionated heparin …

Bivalirudin is an alternative to unfractionated heparin (UFH) anticoagulation during
percutaneous coronary intervention. Previously, we have reported clinical benefit on major …

Background Bivalirudin is an alternative accepted therapy to unfractionated heparin for
patients with myocardial infarction (MI) undergoing percutaneous coronary intervention …